Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310117 | 0.98 | GPR119 (0.67) | GPR119HPGDRECQLEPHX1USP2 | |
| SCHEMBL22284263 | 0.93 | GPR119 (0.58) | GPR119HPGDRECQLEPHX1USP2 | |
| SCHEMBL21359212 | 0.92 | EPHX1 (0.62) | GPR119HPGDRECQLEPHX1USP2 | |
| SCHEMBL992190 | 0.91 | GPR119 (0.57) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL24582050 | 0.91 | GPR119 (0.57) | GPR119HPGDRECQLEPHX1USP2 | |
| SCHEMBL12440604 | 0.91 | GPR119 (0.60) | GPR119HPGDRECQLEPHX1USP2 | |
| SCHEMBL15061065 | 0.91 | GPR119 (0.56) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL8661760 | 0.91 | GPR119 (0.64) | GPR119HPGDRECQLEPHX1USP2 | |
| SCHEMBL15061029 | 0.91 | GPR119 (0.56) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL5567218 | 0.91 | GPR119 (0.60) | GPR119HPGDRECQLEPHX1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695242-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | Meta Pharmaceuticals (HK) Limited (HK) | 2026-02-18 | — | — | EP | disclosed |
| US-20250332156-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-10-30 | — | — | US | disclosed |
| EP-4551556-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | Vividion Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119546575-A | Pharmaceutical compositions comprising WRN helicase inhibitors | 维维迪恩医疗公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024212907-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | META PHARMACEUTICALS (HK) LIMITED (CN) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024010784-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024010784-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| EP-2780337-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-2464228-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2017-12-06 | — | — | EP | disclosed |
| WO-2010084944-A1 | NOVEL PYRROLO[2,3-d]PYRIMIDINE COMPOUND | 田辺三菱製薬株式会社 (JP) | 2010-07-29 | — | — | WO | disclosed |
| US-7408066-B2 | Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING CORPROATION (US) | 2008-08-05 | — | — | US | disclosed |
| US-7408066-B2 | Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING CORPROATION (US) | 2008-08-05 | — | — | US | disclosed |
| US-20070010513-A1 | Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-01-11 | — | — | US | disclosed |
| US-20070010513-A1 | Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-01-11 | — | — | US | disclosed |
| CN-1238765-A | N-(imidazoly (butyl) benzenesulphonamide derivatives with anticoagulation active | SYNTHEBLABO (FR) | 1999-12-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332156-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | GPR119 3365/4885HPGD 654/4885RECQL 1/4885 |
| US-20070010513-A1 | Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | HRH3, HRH4, CHRM1 | GPR119 45/4885HPGD 909/4885RECQL 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.